NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has started its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of epidermolysis bullosa (“EB”). According to the company, this is the first time cannabinol has advanced to a Phase 2 clinical trial to be studied as a therapeutic option to treat a disease. The study will be conducted in seven different countries at 11 sites; the countries include Austria, Germany, Greece, France, Italy, Israel and Serbia. The company has filed clinical trial applications in all seven countries and has received approval from Austria, France, Greece and Israel, with the first site initiation visit being completed at a clinical site in Austria. Screening for eligible participants is set to begin in Austria soon. INM-755 is a cannabinol cream being considered as a topical therapy to treat EB and potentially other dermatological diseases. Currently EB has very few treatment options. “The achievement of this important milestone along the continuum of pharmaceutical drug development in EB supports our belief that this class of compounds hold broad therapeutic potential,” said InMed president and CEO Eric A. Adams in the press release. “This study further demonstrates InMed’s leadership in the development of rare cannabinoids as therapeutic products. In addition, we look forward to achieving key milestones of our second CBN drug candidate for the treatment of glaucoma in the year ahead.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has started its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of epidermolysis bullosa (“EB”). According to the company, this is the first time cannabinol has advanced to a Phase 2 clinical trial to be studied as a therapeutic option to treat a disease. The study will be conducted in seven different countries at 11 sites; the countries include Austria, Germany, Greece, France, Italy, Israel and Serbia. The company has filed clinical trial applications in all seven countries and has received approval from Austria, France, Greece and Israel, with the first site initiation visit being completed at a clinical site in Austria. Screening for eligible participants is set to begin in Austria soon. INM-755 is a cannabinol cream being considered as a topical therapy to treat EB and potentially other dermatological diseases. Currently EB has very few treatment options. “The achievement of this important milestone along the continuum of pharmaceutical drug development in EB supports our belief that this class of compounds hold broad therapeutic potential,” said InMed president and CEO Eric A. Adams in the press release. “This study further demonstrates InMed’s leadership in the development of rare cannabinoids as therapeutic products. In addition, we look forward to achieving key milestones of our second CBN drug candidate for the treatment of glaucoma in the year ahead.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
